Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD PanTumor-101 phase 1 study of risvutatug rezetecan alone and in combinations for advanced solid tumors
jRCT2031240381Phase 1Recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in Nonhematologic neoplasms (3 arms), sponsored by GSK. Primary endpoints: Number of participants with adverse events, Number of participants with dose-limiting toxicities and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240381.